Emily M. Leproust, chief executive officer of Twist Bioscience (TWST), has been a consistent seller of company stock over the past year, with Form 4 filings showing 18 open-market sales since late February 2026 totaling roughly $8.2 million. The largest dispositions came in late May and June, including a $1.58 million sale on May 26, a $1.55 million transaction on May 27, and a $1.79 million sale on June 25. Smaller sales occurred throughout the period, ranging from roughly $10,000 to $517,000, with clusters around option exercises—for instance, on May 26-28 she exercised options valued at about $580,000 and simultaneously sold shares worth over $2.7 million. The pattern is overwhelmingly one-directional: across 40 total filings spanning two companies, Leproust has recorded zero open-market purchases and zero acquisitions, with total sell value reaching $11.2 million.
The only non-sale activity involves compensation-related events at GeneDx (WGS), where she received a grant and exercised options on June 18, 2026, both valued at $0 in the filings—standard equity awards rather than discretionary trades. Her selling in TWST has been steady rather than clustered around any single event, with transactions spread across April, May, and June 2026, including a $366,834 sale on May 21 and a $293,002 sale on May 4. While the option exercises accompanying many of the sales are mechanical, the consistent open-market selling—with no corresponding buys in either TWST or WGS—indicates a clear bias toward reducing her equity position in Twist Bioscience over the trailing months.
AI-assisted summary